US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
US4376110A
(en)
|
1980-08-04 |
1983-03-08 |
Hybritech, Incorporated |
Immunometric assays using monoclonal antibodies
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
EP0088046B1
(de)
|
1982-02-17 |
1987-12-09 |
Ciba-Geigy Ag |
Lipide in wässriger Phase
|
US4816567A
(en)
*
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
EP0143949B1
(en)
|
1983-11-01 |
1988-10-12 |
TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION |
Pharmaceutical composition containing urokinase
|
US4496689A
(en)
*
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
DE3572982D1
(en)
|
1984-03-06 |
1989-10-19 |
Takeda Chemical Industries Ltd |
Chemically modified lymphokine and production thereof
|
US4945050A
(en)
*
|
1984-11-13 |
1990-07-31 |
Cornell Research Foundation, Inc. |
Method for transporting substances into living cells and tissues and apparatus therefor
|
DE3675588D1
(de)
|
1985-06-19 |
1990-12-20 |
Ajinomoto Kk |
Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
|
CA1310924C
(en)
*
|
1986-04-24 |
1992-12-01 |
Francis P. Mccormick |
Infective drug delivery system
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
US5288856A
(en)
*
|
1986-11-20 |
1994-02-22 |
Pierre Amiguet |
Method of isolating acid-stable, biologically active proteins
|
US4970154A
(en)
|
1987-10-09 |
1990-11-13 |
Baylor College Of Medicine |
Method for inserting foreign genes into cells using pulsed radiofrequency
|
DE3889853D1
(de)
|
1987-11-05 |
1994-07-07 |
Hybritech Inc |
Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
|
US4892538A
(en)
*
|
1987-11-17 |
1990-01-09 |
Brown University Research Foundation |
In vivo delivery of neurotransmitters by implanted, encapsulated cells
|
US5106627A
(en)
*
|
1987-11-17 |
1992-04-21 |
Brown University Research Foundation |
Neurological therapy devices
|
US5011472A
(en)
*
|
1988-09-06 |
1991-04-30 |
Brown University Research Foundation |
Implantable delivery system for biological factors
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
JP2989002B2
(ja)
|
1988-12-22 |
1999-12-13 |
キリン―アムジエン・インコーポレーテツド |
化学修飾顆粒球コロニー刺激因子
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5288855A
(en)
|
1989-01-23 |
1994-02-22 |
Farmitalia Carlo Erba |
Extracellular form of the human fibroblast growth factor receptor
|
EP0481000B1
(en)
*
|
1989-07-06 |
1999-05-12 |
The Regents Of The University Of California |
Receptors for fibroblast growth factors
|
US5676954A
(en)
*
|
1989-11-03 |
1997-10-14 |
Vanderbilt University |
Method of in vivo delivery of functioning foreign genes
|
US5272071A
(en)
|
1989-12-22 |
1993-12-21 |
Applied Research Systems Ars Holding N.V. |
Method for the modification of the expression characteristics of an endogenous gene of a given cell line
|
US5672510A
(en)
*
|
1990-01-19 |
1997-09-30 |
Genetic Therapy, Inc. |
Retroviral vectors
|
ES2204886T3
(es)
*
|
1990-07-06 |
2004-05-01 |
Gencell S.A. |
Receptores de factor de crecimiento fibroblastico.
|
US5217889A
(en)
*
|
1990-10-19 |
1993-06-08 |
Roninson Igor B |
Methods and applications for efficient genetic suppressor elements
|
US5252714A
(en)
*
|
1990-11-28 |
1993-10-12 |
The University Of Alabama In Huntsville |
Preparation and use of polyethylene glycol propionaldehyde
|
US5229501A
(en)
*
|
1991-01-11 |
1993-07-20 |
Chiron Corporation |
Expression and use of human fibroblast growth factor receptor
|
US6565841B1
(en)
|
1991-03-15 |
2003-05-20 |
Amgen, Inc. |
Pulmonary administration of granulocyte colony stimulating factor
|
IL100219A0
(en)
|
1991-12-02 |
1992-09-06 |
Yeda Res & Dev |
Variable region within fibroblast growth factor receptors that confers ligand specificity
|
WO1993015722A1
(en)
|
1992-02-07 |
1993-08-19 |
Syntex (Usa) Inc. |
Controlled delivery of pharmaceuticals from preformed porous microparticles
|
US5234784A
(en)
*
|
1992-04-01 |
1993-08-10 |
Eastman Kodak Company |
Method of making a projection viewable transparency comprising an electrostatographic toner image
|
US5364791A
(en)
|
1992-05-14 |
1994-11-15 |
Elisabetta Vegeto |
Progesterone receptor having C. terminal hormone binding domain truncations
|
US5489743A
(en)
*
|
1993-01-19 |
1996-02-06 |
Amgen Inc. |
Transgenic animal models for thrombocytopenia
|
US5581476A
(en)
*
|
1993-01-28 |
1996-12-03 |
Amgen Inc. |
Computer-based methods and articles of manufacture for preparing G-CSF analogs
|
GB9313210D0
(en)
*
|
1993-06-25 |
1993-08-11 |
Sandoz Ltd |
Novel combinations
|
US6664107B1
(en)
*
|
1993-05-26 |
2003-12-16 |
Ontario Cancer Institute, University Health Network |
CD45 disrupted nucleic acid
|
CA2165162C
(en)
*
|
1993-06-14 |
2000-05-23 |
Hermann Bujard |
Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
|
US5589362A
(en)
|
1993-06-14 |
1996-12-31 |
Basf Aktiengesellschaft |
Tetracycline regulated transcriptional modulators with altered DNA binding specificities
|
US5654168A
(en)
*
|
1994-07-01 |
1997-08-05 |
Basf Aktiengesellschaft |
Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
|
US5484720A
(en)
*
|
1994-09-08 |
1996-01-16 |
Genentech, Inc. |
Methods for calcium phosphate transfection
|
US5824784A
(en)
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
US5679559A
(en)
*
|
1996-07-03 |
1997-10-21 |
University Of Utah Research Foundation |
Cationic polymer and lipoprotein-containing system for gene delivery
|
US6214795B1
(en)
*
|
1996-11-12 |
2001-04-10 |
Praecis Pharmaceuticals, Inc. |
Peptide compounds useful for modulating FGF receptor activity
|
CA2276108C
(en)
*
|
1996-12-26 |
2009-03-03 |
Kyowa Hakko Kogyo Co., Ltd. |
Novel peptide, novel dna, and novel antibody
|
US6133426A
(en)
|
1997-02-21 |
2000-10-17 |
Genentech, Inc. |
Humanized anti-IL-8 monoclonal antibodies
|
CA2309783C
(en)
|
1997-11-25 |
2011-06-28 |
Genentech, Inc. |
Fibroblast growth factor-19
|
US6150098A
(en)
|
1998-02-20 |
2000-11-21 |
Amgen Inc. |
Methods for identifying novel secreted mammalian polypeptides
|
US6548634B1
(en)
*
|
1998-09-30 |
2003-04-15 |
Chiron Corporation |
Synthetic peptides having FGF receptor affinity
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
WO2000027885A1
(fr)
|
1998-11-05 |
2000-05-18 |
Kyowa Hakko Kogyo Co., Ltd. |
Nouveau popypeptide chimerique
|
AU3224700A
(en)
|
1999-02-08 |
2000-08-25 |
Chiron Corporation |
Fibroblast growth factor receptor-immunoglobulin fusion
|
CA2311201A1
(en)
*
|
1999-08-05 |
2001-02-05 |
Genset S.A. |
Ests and encoded human proteins
|
US7408047B1
(en)
*
|
1999-09-07 |
2008-08-05 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US7459540B1
(en)
*
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
WO2001018209A1
(en)
|
1999-09-10 |
2001-03-15 |
Curagen Corporation |
Fibroblast growth factor polypeptide and nucleic acids encoding same
|
WO2001032678A1
(en)
*
|
1999-11-05 |
2001-05-10 |
Smithkline Beecham Corporation |
sbgFGF-19a
|
US6716626B1
(en)
*
|
1999-11-18 |
2004-04-06 |
Chiron Corporation |
Human FGF-21 nucleic acids
|
ATE446365T1
(de)
|
1999-11-18 |
2009-11-15 |
Novartis Vaccines & Diagnostic |
Menschliches fgf-21 gen und genexpressionsprodukte
|
US7108984B2
(en)
*
|
2000-01-12 |
2006-09-19 |
Mount Sinai School Of Medicine |
Methods of identifying modulators of the FGF receptor
|
AU2631001A
(en)
|
2000-01-05 |
2001-07-16 |
Zymogenetics Inc. |
Novel fgf homolog zfgf11
|
US20020081663A1
(en)
|
2000-01-05 |
2002-06-27 |
Conklin Darrell C. |
Novel FGF homolog ZFGF11
|
IL139380A0
(en)
|
2000-10-31 |
2001-11-25 |
Prochon Biotech Ltd |
Active variants of fibroblast growth factor
|
US20060223114A1
(en)
*
|
2001-04-26 |
2006-10-05 |
Avidia Research Institute |
Protein scaffolds and uses thereof
|
US20040018499A1
(en)
*
|
2001-06-06 |
2004-01-29 |
Lal Preeti G |
Extracellular messengers
|
WO2002102973A2
(en)
*
|
2001-06-20 |
2002-12-27 |
Prochon Biotech Ltd. |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
ATE468862T1
(de)
*
|
2001-07-11 |
2010-06-15 |
Maxygen Inc |
G-csf konjugate
|
WO2003011213A2
(en)
|
2001-07-30 |
2003-02-13 |
Eli Lilly And Company |
Method for treating diabetes and obesity
|
WO2003038054A2
(en)
*
|
2001-10-31 |
2003-05-08 |
New York University |
Structure-based design and synthesis of fgf inhibitors and fgf modulator compounds
|
JP3990972B2
(ja)
*
|
2001-11-20 |
2007-10-17 |
有限会社 キック |
血管再狭窄防止薬及び該防止薬がコーティングされた血管内埋め込み器具
|
EP1469880A4
(en)
*
|
2002-01-15 |
2006-04-26 |
Lilly Co Eli |
METHOD FOR REDUCING MORBIDITY AND MORTALITY IN CRITELY SICK PATIENTS
|
US7531304B2
(en)
*
|
2002-01-31 |
2009-05-12 |
Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. |
Method for screening FGFR-4 agonists
|
EP1332761A1
(en)
*
|
2002-01-31 |
2003-08-06 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Agonists of fibroblast growth factor receptors (FGFR)
|
AU2003265057A1
(en)
|
2002-09-04 |
2004-03-29 |
Abtech |
Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy
|
AU2003284357A1
(en)
|
2002-11-01 |
2004-06-07 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
JP2007524566A
(ja)
*
|
2002-12-20 |
2007-08-30 |
エンカム ファーマシューティカルズ アクティーゼルスカブ |
レセプターとリガンドの間の相互作用の調節の方法
|
TWI300430B
(en)
*
|
2003-01-10 |
2008-09-01 |
Ritek Corp |
Optical recording medium dye and optical recording medium using thereof
|
WO2004083381A2
(en)
|
2003-03-13 |
2004-09-30 |
Indiana University Advanced Research & Technology Institute |
Fibroblast growth factor receptor-1 polynucleotides, polypeptides, and mutants
|
US20040185499A1
(en)
*
|
2003-03-20 |
2004-09-23 |
Jolley Michael E. |
Method of epitope scanning using fluorescence polarization
|
JP2006240990A
(ja)
|
2003-05-15 |
2006-09-14 |
Kirin Brewery Co Ltd |
klothoタンパク質および抗klothoタンパク質抗体ならびにそれらの用途
|
AU2004251145C1
(en)
*
|
2003-06-12 |
2011-04-14 |
Eli Lilly And Company |
GLP-1 analog fusion proteins
|
WO2004110472A2
(en)
|
2003-06-12 |
2004-12-23 |
Eli Lilly And Company |
Fusion proteins
|
WO2005037235A2
(en)
|
2003-10-16 |
2005-04-28 |
Imclone Systems Incorporated |
Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
|
EP1702067A1
(en)
*
|
2003-12-10 |
2006-09-20 |
Eli Lilly And Company |
Muteins of fibroblast growth factor 21
|
JP4568896B2
(ja)
*
|
2003-12-16 |
2010-10-27 |
財団法人くまもとテクノ産業財団 |
抗hiv抗体
|
AU2004312376A1
(en)
|
2003-12-19 |
2005-07-21 |
Five Prime Therapeutics, Inc. |
Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
|
EP1727559A1
(en)
|
2004-01-26 |
2006-12-06 |
Eli Lilly And Company |
Use of fgf-21 and a thiazolidinedione for treating type 2 diabetes
|
EP1735340A2
(en)
|
2004-03-17 |
2006-12-27 |
Eli Lilly And Company |
Glycol linked fgf-21 compounds
|
JP4505631B2
(ja)
*
|
2004-03-31 |
2010-07-21 |
独立行政法人産業技術総合研究所 |
ヘパラン硫酸糖鎖を付加したヘパリン結合性タンパク質、その製造方法及びそれを含有する医薬組成物
|
WO2005113606A2
(en)
|
2004-05-13 |
2005-12-01 |
Eli Lilly And Company |
Fgf-21 fusion proteins
|
WO2006028595A2
(en)
*
|
2004-09-02 |
2006-03-16 |
Eli Lilly And Company |
Muteins of fibroblast growth factor 21
|
WO2006028714A1
(en)
|
2004-09-02 |
2006-03-16 |
Eli Lilly And Company |
Muteins of fibroblast growth factor 21
|
US20080176790A1
(en)
|
2004-10-29 |
2008-07-24 |
Defrees Shawn |
Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
|
JP2008522617A
(ja)
|
2004-12-14 |
2008-07-03 |
イーライ リリー アンド カンパニー |
線維芽細胞成長因子21の突然変異タンパク質
|
JP2008528487A
(ja)
|
2005-01-21 |
2008-07-31 |
イーライ リリー アンド カンパニー |
心臓血管疾患を治療する方法
|
JP2006246823A
(ja)
|
2005-03-11 |
2006-09-21 |
Kyoto Univ |
造血因子としてのFgf21の使用
|
WO2006130527A2
(en)
|
2005-05-31 |
2006-12-07 |
Novartis Ag |
Mutations and polymorphisms of fibroblast growth factor receptor 1
|
ES2336832T3
(es)
*
|
2005-07-22 |
2010-04-16 |
Five Prime Therapeutics, Inc. |
Composiciones y procedimientos para tratar enfermedades con proteinas de fusion de fgfr.
|
JP2009504183A
(ja)
*
|
2005-08-15 |
2009-02-05 |
ジェネンテック・インコーポレーテッド |
遺伝子破壊、それに関連する組成物および方法
|
US8043833B2
(en)
|
2005-10-31 |
2011-10-25 |
Novo Nordisk A/S |
Expression of soluble therapeutic proteins
|
CA2644046A1
(en)
|
2006-02-28 |
2007-09-07 |
Trustees Of Boston University |
Metabolic regulators and uses thereof
|
US8101721B2
(en)
*
|
2006-06-15 |
2012-01-24 |
Fibron Ltd. |
Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
|
CN101516388B
(zh)
*
|
2006-07-21 |
2012-10-31 |
诺和诺德公司 |
通过o-联糖基化序列的肽的糖基化
|
US8969532B2
(en)
*
|
2006-10-03 |
2015-03-03 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
|
JP2008108334A
(ja)
*
|
2006-10-24 |
2008-05-08 |
Funai Electric Co Ltd |
再生装置およびプログラム
|
KR101476472B1
(ko)
|
2007-03-30 |
2015-01-05 |
암브룩스, 인코포레이티드 |
변형된 fgf-21 폴리펩티드 및 그 용도
|
PL2550972T3
(pl)
*
|
2007-04-02 |
2018-08-31 |
Genentech, Inc. |
Przeciwciało agonistyczne Klotho-beta do stosowania w leczeniu cukrzycy lub insulinooporności
|
JP5187837B2
(ja)
*
|
2007-04-06 |
2013-04-24 |
独立行政法人産業技術総合研究所 |
補助因子による受容体の活性化方法並びにリガンド活性の利用方法
|
US7537903B2
(en)
*
|
2007-04-23 |
2009-05-26 |
Board Of Regents, The University Of Texas System |
FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner
|
JP2010529954A
(ja)
|
2007-05-22 |
2010-09-02 |
ノバルティス アーゲー |
Fgf21関連障害を処置、診断および検出する方法
|
US8481497B2
(en)
|
2007-05-29 |
2013-07-09 |
Sapporo Medical University |
Therapeutic agent for cancer, and method for treatment of cancer
|
JP2010531135A
(ja)
|
2007-06-04 |
2010-09-24 |
ノボ ノルディスク アクティーゼルスカブ |
N−アセチルグルコサミニルトランスフェラーゼを使用したo結合型グリコシル化
|
EP3260129A1
(en)
|
2007-08-03 |
2017-12-27 |
Eli Lilly and Company |
An fgf-21 compound and a glp-1 compound for use in the treatment of obesity
|
TW200936156A
(en)
*
|
2008-01-28 |
2009-09-01 |
Novartis Ag |
Methods and compositions using Klotho-FGF fusion polypeptides
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
WO2010006214A1
(en)
|
2008-07-09 |
2010-01-14 |
Ambrx, Inc. |
Fgf-21 neutralizing antibodies and their uses
|
WO2010017198A2
(en)
*
|
2008-08-04 |
2010-02-11 |
Five Prime Therapeutics, Inc. |
Fgfr extracellular domain acidic region muteins
|
SI3248610T1
(sl)
|
2009-05-05 |
2024-03-29 |
Amgen Inc., |
Mutanti fgf21 in njihove uporabe
|
MX368790B
(es)
|
2009-10-15 |
2019-10-16 |
Genentech Inc |
Factores de crecimiento de fibroblasto quimericos con especificidad de receptor alterada.
|